OGEN · XBRL financial data
Oragenics financial statements, every fiscal year
The same tables from 7 filings, lined up. Matched by XBRL tag: renamed lines keep their history.
How these numbers work
- Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
- Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
- * marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
- 0 means a filing states zero; a dash (—) means no filing states that number.
- “year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
- Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
- Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
- Shares outstanding come from each filing's cover page, as of the date printed there.
- Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.
Income statement
CSVFiscal years (OGEN's year ends in late December)
| In thousands of dollars | Dec 31, 2020 | Dec 31, 2021 | †Dec 31, 2022 | Dec 31, 2023 | Dec 31, 2024 | †Dec 31, 2025 |
|---|---|---|---|---|---|---|
| Revenue from contracts with customers | — | 87 | 132 | 38 | — | — |
| Research and development | 22,108 | 10,586 | 10,073 | 15,491 | 4,114 | 2,393 |
| General and administrative | 4,534 | 5,272 | 4,474 | 5,452 | 6,444 | 6,970 |
| Total operating expenses | 26,641 | 15,858 | 14,547 | 20,943 | 10,559 | 9,363 |
| Operating income (loss) | (26,641) | (15,771) | (14,416) | (20,905) | (10,559) | (9,363) |
| Interest income | 89 | 76 | 136 | 210 | 46 | 182 |
| Interest expense | 11 | 16 | 15 | 31 | 30 | 786 |
| Other income (expense) | 2 | 1 | 12 | 69 | — | — |
| Income tax expense (benefit) | — | — | — | — | — | (137) |
| Net income (loss) | (26,431) | (15,712) | (14,288) | (20,656) | (10,568) | (9,842) |
| Earnings per share, basic USD per share | (0.47) | (0.14) | (7.11) | (9.18) | (1.60) | (4.56) |
| Earnings per share, diluted USD per share | — | — | (7.11) | (9.18) | (1.60) | (4.56) |
| Weighted average shares, basic thousands of shares | 56,531 | 112,920 | 2,009 | 2,250 | 6,622 | 2,157 |
| Weighted average shares, diluted thousands of shares | — | — | 2,009 | 2,250 | 6,622 | 2,157 |
- † Share count changed about 1/57 in the period ending 2022-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
- † Share count changed about 1/5 in the period ending 2025-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
Balance sheet
CSVFiscal years (OGEN's year ends in late December)
| In thousands of dollars | Dec 31, 2020 | Dec 31, 2021 | †Dec 31, 2022 | Dec 31, 2023 | Dec 31, 2024 | †Dec 31, 2025 |
|---|---|---|---|---|---|---|
| Cash and cash equivalents | 17,640 | 27,266 | 11,427 | 3,484 | 865 | 4,400 |
| Short-term investments | — | — | — | — | — | 4,000 |
| Prepaid and other current assets | 343 | 435 | 2,863 | 382 | 608 | 1,615 |
| Total current assets | 17,983 | 27,707 | 14,290 | 3,866 | 1,473 | 10,068 |
| Property and equipment, net | 43 | 46 | 121 | 0 | — | — |
| Right-of-use asset | 655 | 478 | 347 | 10 | — | — |
| Total assets | 18,681 | 28,231 | 14,758 | 4,966 | 1,473 | 10,068 |
| Accrued liabilities | — | — | 813 | 223 | 203 | — |
| Total current liabilities | 1,342 | 1,445 | 1,596 | 1,798 | — | — |
| Total deposits | — | 18 | 18 | — | — | — |
| Lease liability, non-current | 494 | 300 | 152 | — | — | — |
| Total liabilities | — | — | — | 1,798 | 1,684 | 1,786 |
| Accumulated deficit | (154,445) | (171,274) | (185,563) | (206,218) | (216,786) | (226,629) |
| Total stockholders' equity | 16,845 | 26,486 | 13,009 | 3,168 | (212) | 8,281 |
| Total liabilities and equity | 18,681 | 28,231 | 14,758 | 4,966 | 1,473 | 10,068 |
| Common shares outstanding (cover page) thousands of shares | 109,646 | 116,395 | 2,025 | 4,481 | 21,475 | 4,336 |
- † Share count changed about 1/57 in the period ending 2022-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
- † Share count changed about 1/5 in the period ending 2025-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
Cash flows
CSVFiscal years (OGEN's year ends in late December)
| In thousands of dollars | Dec 31, 2020 | Dec 31, 2021 | †Dec 31, 2022 | Dec 31, 2023 | Dec 31, 2024 | †Dec 31, 2025 |
|---|---|---|---|---|---|---|
| Net income (loss) | (26,431) | (15,712) | (14,288) | (20,656) | (10,568) | (9,842) |
| Stock-based compensation | 1,491 | 1,688 | 742 | 1,017 | 516 | 642 |
| Net cash from operating activities | (16,953) | (13,470) | (15,228) | (7,291) | (8,597) | (9,246) |
| Purchases of property and equipment | — | 44 | 128 | — | — | — |
| Net cash from investing activities | — | (44) | (116) | (936) | — | — |
| Proceeds from issuing common stock | 11,339 | 26,676 | 69 | — | 6,672 | 2,634 |
| Proceeds from issuing equity | 11,339 | 12,500 | 92,000 | 800 | 7,650 | 2,600 |
| Proceeds from long-term debt | — | — | — | — | — | 2,200 |
| Net cash from financing activities | 16,324 | 23,140 | (495) | 284 | 5,979 | 16,781 |
| Net change in cash | (628) | 9,626 | (15,839) | (7,943) | (2,619) | 7,535 |
- † Share count changed about 1/57 in the period ending 2022-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
- † Share count changed about 1/5 in the period ending 2025-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
Compare with peers
SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.
How peers are chosen
- SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
- Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
- Runway shows only for companies burning cash with under $10B of public float.
- * marks a quarter worked out from the filing totals: for a 10-K, the year less the first three quarters; for a 10-Q, the year-to-date total less the earlier one.
- A cell reading “not reported” means the filings give no figure for that quarter alone.
| Company | Cash ($K) | Revenue, quarter ($K) | Operating cash flow, quarter ($K) | Shares outstanding | Runway | Quarter |
|---|---|---|---|---|---|---|
| Oragenics | 3,864 | not reported | (2,187)* | 4.5M | 1.8 quarters | 10-QJun 30, 2026 |
| MetaVia | 12,634 | not reported | (3,762)* | 6.6M | 3.4 quarters | 10-QJun 30, 2026 |
| Inhibitor Therapeutics | 516 | not reported | (775)* | 173.8M | 0.7 quarters | 10-QJun 30, 2026 |
| PTC Therapeutics | 508,894 | 357,807 | (25,311)* | 83.5M | — | 10-QSep 30, 2026 |
| Integrated Biopharma | 4,471 | not reported | (1,194)* | 31.1M | 3.7 quarters | 10-KJun 30, 2026 |
| Enveric Biosciences | 8,296 | not reported | (2,445)* | 4.5M | 3.4 quarters | 10-QJun 30, 2026 |
| Polomar Health Services | 179 | 1,529 | 121* | 28.4M | — | 10-QJun 30, 2026 |
| Q/C Technologies | 308 | not reported | (1,819)* | 8.2M | 6.0 quarters | 10-QJun 30, 2026 |
| Propanc Biopharma | 832 | not reported | (1,602)* | 6.3M | 0.5 quarters | 10-KJun 30, 2026 |
Not investment advice. Not affiliated with the U.S. SEC.